|
Subjects, n
|
12
|
12
|
12
| | |
|
Age, years
|
52 (45 to 57)
|
45 (39 to 55)
|
49 (40 to 56)
|
ns
|
ns
|
|
Male, n (%)
|
7 (58%)
|
6 (50%)
|
8 (67%)
|
ns
|
ns
|
|
ATSI, n (%)
|
10 (83%)
|
7 (58%)
|
8 (67%)
|
ns
|
ns
|
|
APACHE II score, day 0
|
20 (29 to 23)
|
8 (4 to 14)
| |
<0.0001
|
N/A
|
|
SOFA score, day 0
|
10 (4 to 10)
|
1 (0 to 2)
| |
<0.0001
|
N/A
|
|
Plasma L-arginine, μM
|
39 (25 to 53)
|
40 (21 to 48)
|
74 (65 to 88)
|
ns
|
<0.0001
|
|
Plasma IL-6, pg/mL
|
1433 (400 to 4290)
|
82 (42 to 302)
|
5 (5 to 5)
|
<0.0001
|
<0.0001
|
|
Plasma IL-10 (pg/mL), median (range)
|
65 (5 to 9525)
|
5 (5 to 72)
|
5 (5)
|
0.001
|
0.004
|
|
Plasma VEGF, pg/mL
|
89 (16 to 115)
|
79 (62 to 138)
|
51 (32 to 71)
|
ns
|
0.03
|
|
Plasma arginase, μmol/mL/hr
|
0.18 (0.1 to 0.23)*
|
0.19 (0.12 to 0.26)
|
0.14 (0.09 to 0.16)
|
ns
|
ns
|
|
Interphase-neutrophils (%)
|
19.2 (4.4 to 29.5)
|
2.7 (1.5 to 6.1)
|
1.5 (0 to 2.0)
|
0.02
|
0.001
|
|
Neutrophil × 103/μL
|
13.1 (7.2 to 19.4)
|
14.2 (11.4 to 16.6)
|
6 (4.0 to 9.6)
|
ns
|
0.02
|
|
Imm. granulocyte × 103/μL, median (range)
|
0.4 (0 to 11.8)
|
0 (0 to 7.6)
|
0 (0 to 0)
|
0.05
|
N/A
|
|
Monocyte × 103/μL
|
0.45 (0.1 to 1.2)
|
0.65 (0.4 to 1)
|
0.55 (0.5 to 0.7)
|
ns
|
ns
|
|
Lymphocyte × 103/μL
|
1.2 (0.5 to 2.1)
|
1.2 (0.8 to 1.6)
|
2.2 (1.5 to 2.4)
|
ns
|
ns
|
|
Causative organism, n (%)
| | | | | |
|
None cultured
|
5 (42%)
|
9 (75%)
| | | |
|
Gram-positive bacteria
|
4 (33%)
|
2 (17%)
| | | |
|
Gram-negative bacteria
|
3 (25%)
|
1 (8%)
| | | |
